S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

Genocea Biosciences Stock Forecast, Price & News

+0.01 (+1.04%)
(As of 01/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
579,081 shs
Average Volume
238,712 shs
Market Capitalization
$55.72 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Genocea Biosciences logo

About Genocea Biosciences

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The firm uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.36 million
Book Value
$0.17 per share


Net Income
$-43.71 million
Pretax Margin




Free Float
Market Cap
$55.72 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.83 out of 5 stars

Medical Sector

802nd out of 1,415 stocks

Biological Products, Except Diagnostic Industry

127th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

Is Genocea Biosciences a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Genocea Biosciences stock.
View analyst ratings for Genocea Biosciences
or view top-rated stocks.

How has Genocea Biosciences' stock been impacted by Coronavirus (COVID-19)?

Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNCA stock has decreased by 47.0% and is now trading at $0.97.
View which stocks have been most impacted by COVID-19

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Genocea Biosciences

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) issued its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter. During the same period last year, the company posted ($0.26) earnings per share.
View Genocea Biosciences' earnings history

What price target have analysts set for GNCA?

3 equities research analysts have issued twelve-month target prices for Genocea Biosciences' stock. Their forecasts range from $6.00 to $8.00. On average, they expect Genocea Biosciences' share price to reach $6.67 in the next twelve months. This suggests a possible upside of 587.3% from the stock's current price.
View analysts' price targets for Genocea Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the following people:
  • Chip Clark, President, Chief Executive Officer & Director
  • Diantha Duvall, Chief Financial Officer
  • Jessica Baker Flechtner, Chief Scientific Officer
  • Thomas Andrew Davis, Chief Medical Officer
  • Jacquelyn Sumer, Chief Legal & Compliance Officer

What is William Clark's approval rating as Genocea Biosciences' CEO?

5 employees have rated Genocea Biosciences CEO William Clark on Glassdoor.com. William Clark has an approval rating of 82% among Genocea Biosciences' employees.

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $0.97.

How much money does Genocea Biosciences make?

Genocea Biosciences has a market capitalization of $55.72 million and generates $1.36 million in revenue each year. The biotechnology company earns $-43.71 million in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Genocea Biosciences have?

Genocea Biosciences employs 72 workers across the globe.

What is Genocea Biosciences' official website?

The official website for Genocea Biosciences is www.genocea.com.

Where are Genocea Biosciences' headquarters?

Genocea Biosciences is headquartered at 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at (617) 876-8191, via email at [email protected], or via fax at 617-876-8192.

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.